“Advancing Melanoma Care: Early Identification, Timely Action, and Next-Generation Therapy,” is an educational video series focusing on earlier identification of advanced melanoma, routine HLA-A*02:01 testing, and timely referral to IMA203 (anzu-cel) trial sites. In “Why New Options & Early Action Matter,” Alison Betof, MD, PhD, FASCO—Director, Melanoma Program, Mark and Mary Stevens Endowed Scholar in Melanoma, and Director, Solid Tumor Cellular Therapy at Stanford University School of Medicine—discusses why early action is critical following first-line immune checkpoint inhibitor therapy, as clinical decline and immune exhaustion may limit access to next-line treatment options if action is delayed. Topics in this brief educational video include the need for additional therapy after first-line treatment, declining T-cell fitness with each line of therapy, and why earlier identification and testing may help preserve access to emerging therapies. Watch the first segment of the series to gain insight into why proactive planning, early testing, and timely referral are increasingly important in the evolving treatment landscape for advanced melanoma.